Triple Negative Breast Cancer

Showing NaN - NaN of 43

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer Trial in Oklahoma City, Houston (AO-252)

Recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Oklahoma City, Oklahoma
  • +1 more
Nov 13, 2023

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

Recruiting
  • Triple Negative Breast Cancer
  • +14 more
  • LYL797
  • Scottsdale, Arizona
  • +10 more
Jan 30, 2023

Triple Negative Breast Cancer, PD-L1 Negative Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Paclitaxel,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Negative
  • Sacituzumab Govitecan-hziy
  • +4 more
  • Anchorage, Alaska
  • +231 more
Jan 17, 2023

Triple Negative Breast Cancer, PD-L1 Positive Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Pembrolizumab,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Positive
  • Sacituzumab Govitecan-hziy
  • +5 more
  • Anchorage, Alaska
  • +245 more
Jan 12, 2023

NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)

Recruiting
  • Non-small Cell Lung Cancer
  • +11 more
  • Birmingham, Alabama
  • +32 more
Jan 4, 2023

Colorectal Cancer, NSCLC, Triple Negative Breast Cancer Trial in Spain, United Kingdom, United States (GEN1029

Terminated
  • Colorectal Cancer
  • +6 more
  • GEN1029 (HexaBody®-DR5/DR5)
  • New Haven, Connecticut
  • +5 more
Nov 11, 2022

Squamous Cell Carcinoma of Head and Neck, NSCLC, Hepatocellular Carcinoma Trial in Worldwide (KY1044, KY1044 and atezolizumab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +11 more
  • New Haven, Connecticut
  • +12 more
Nov 3, 2022

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial in United States (Paclitaxel, CB-839)

Completed
  • Triple Negative Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • Birmingham, Alabama
  • +24 more
Sep 19, 2022

Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer Trial in Worldwide (BT5528,

Recruiting
  • Advanced Solid Tumor Historically Known for High EphA2 Expression
  • +6 more
  • Encinitas, California
  • +27 more
Aug 17, 2022

Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer Trial in Huntersville, Houston, Webster (PT199, Anti-PD-1 mAb)

Recruiting
  • Advanced Solid Tumor
  • +18 more
  • PT199
  • Anti-PD-1 monoclonal antibody
  • Huntersville, North Carolina
  • +2 more
Aug 10, 2022

Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)

Recruiting
  • Bone Sarcoma
  • +15 more
  • Aldesleukin
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 3, 2022

Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer Trial in Worldwide (PDR001)

Completed
  • Melanoma
  • +4 more
  • PDR001
  • Baltimore, Maryland
  • +40 more
Aug 2, 2022

Triple Negative Breast Cancer Trial in Canada, United States (Placebo, Atezolizumab)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Mobile, Alabama
  • +216 more
Jul 27, 2022

NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • CART-TnMUC1
  • +2 more
  • Phoenix, Arizona
  • +9 more
Jul 18, 2022

Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer Trial in Worldwide (INCB106385, INCMGA00012)

Recruiting
  • Ovarian Cancer
  • +10 more
  • West Hollywood, California
  • +27 more
Jun 27, 2022

Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in Japan, United States (Datopotamab

Recruiting
  • Hormone Receptor Positive Breast Cancer
  • +2 more
  • Datopotamab Deruxtecan (Dato-DXd)
  • Los Angeles, California
  • +13 more
Jun 21, 2022

Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (Combination of NKTR-214 + nivolumab)

Completed
  • Melanoma
  • +6 more
  • Combination of NKTR-214 + nivolumab
  • La Jolla, California
  • +57 more
Jun 22, 2022

Breast Cancer, Breast Tumor, Breast Cancer Female Trial in Houston (Paclitaxel, Carboplatin, Trastuzumab)

Not yet recruiting
  • Breast Cancer
  • +10 more
  • Houston, Texas
  • +1 more
May 15, 2022

Tumor Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer Trial in United States (XL102, Fulvestrant,

Recruiting
  • Neoplasm Malignant
  • +4 more
  • Atlanta, Georgia
  • +4 more
Apr 19, 2022

Triple Negative Breast Cancer, Anthracycline-refractory TNBC Trial in Houston (Docetaxel, Pembrolizumab, IL-12 gene therapy)

Suspended
  • Triple Negative Breast Cancer
  • Anthracycline-refractory TNBC
  • Houston, Texas
    Houston Methodist Cancer Center
Mar 28, 2022

Triple Negative Breast Cancer Trial in United States (Cisplatin, Paclitaxel)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Birmingham, Alabama
  • +19 more
Feb 14, 2022